GlassScriptPhysician profile
Sharanjit Kaur
NPI 1346611993
$6,688.16
in general payments reported to CMS, 2019-2025
49 companies · $962 in 2025
The $962 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $703 · 2021: $1,378 · 2022: $1,532 · 2023: $1,006 · 2024: $849 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.22 |
| Education | $380.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,627.63 | 2020-2025 | Rayaldee |
| Amgen INC. | $651.21 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $594.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $534.03 | 2020-2025 | |
| Novo Nordisk INC | $484.06 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Vifor Pharma, INC. | $342.22 | 2020-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.29 | 2020-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $207.42 | 2020-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $186.37 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $157.33 | 2020-2025 | Verquvo, Capvaxive, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $146.14 | 2021-2024 | |
| Lilly USA, LLC | $138.61 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Corcept Therapeutics | $108.61 | 2021-2025 | Korlym |
| Mannkind Corporation | $96.05 | 2020-2025 | |
| Abbott Laboratories | $86.20 | 2024-2025 | Freestyle Libre 3, Aveir, Mitraclip |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $86.13 | 2022-2024 | Strensiq, Ultomiris |
| Horizon Therapeutics Plc | $53.45 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $47.65 | 2023-2025 | Unithroid |
| Madrigal Pharmaceuticals | $45.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Astellas Pharma US INC | $44.33 | 2019-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $41.35 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.08 | 2022-2025 | Entyvio |
| Genzyme Corporation | $40.38 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $39.97 | 2020-2021 | |
| Rhythm Pharmaceuticals, INC. | $37.90 | 2025 | Imcivree |
| Intuity Medical INC | $37.84 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Janssen Pharmaceuticals, INC | $36.52 | 2021 | |
| Dexcom, INC. | $35.48 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $34.16 | 2020 | |
| Renalytix Ai, INC. | $32.40 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Shire North American Group INC | $30.76 | 2019 | |
| Travere Therapeutics, INC. | $29.09 | 2021-2022 | |
| Pfizer INC. | $27.15 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $24.08 | 2021 | |
| Bausch Health US, LLC | $23.89 | 2020 | |
| Ardelyx, INC. | $23.67 | 2024 | Ibsrela |
| Conmed Corporation | $23.65 | 2025 | Conmed Biliary |
| Sumitomo Pharma America, INC. | $22.06 | 2024 | Gemtesa |
| Kiniksa Pharmaceuticals International, Plc | $21.98 | 2024 | Arcalyst |
| Medtronic, INC. | $20.59 | 2024 | Minimed 780g |
| Lexicon Pharmaceuticals, INC. | $20.24 | 2024 | |
| Esperion Therapeutics, INC. | $19.03 | 2023 | Nexletol |
| Glaxosmithkline, LLC. | $18.63 | 2023 | Arexvy, Shingrix |
| Scpharmaceuticals INC. | $17.82 | 2025 | |
| Eisai INC. | $17.02 | 2025 | |
| Ibsa Pharma INC. | $16.80 | 2021 | |
| Virtus Pharmaceuticals LLC | $13.74 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.74 | 2024 | Edarbi |
| Redhill Biopharma INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharanjit Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.